Study to Assess the Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

382 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Study Completion Date

2014-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the treatment patterns in participants with metastatic castration-resistant prostate cancer (mCRPC). Additionally, participant's demographic and clinical characteristics, skeletal-related events, criteria used to define CRPC, prostate specific antigen (PSA) levels and pain related to disease and overall survival will be observed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care

NCT02236637

Prostate Cancer

COMPLETED

Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer

NCT02008058

Metastatic Castrate-Resistant Prostate Cancer

COMPLETED

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

NCT04506567

Prostate Cancer

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer

NCT02066961

Prostate Cancer Castration-resistant Prostate Cancer Metastatic Prostate Cancer

COMPLETED

Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients

NCT01076751

Prostatic Neoplasms

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an observational (study in which participants identified as belonging to study groups are assessed for biomedical or health outcomes), longitudinal (correlational research study that involves repeated observations of the same variables over long periods of time) and retrospective (study looking back over past experience) study to describe the treatment patterns in mCRPC. Treatment patterns will be assessed by collecting medical charts from participants diagnosed with mCRPC in or prior 2009. Primarily, percentage of participants who received therapy as first line treatment will be assessed. All adverse events associated with the use of Sponsor drugs will be reported.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostatic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metastatic Castration-resistant Prostate Cancer

Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.

No Intervention

Intervention Type OTHER

Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No Intervention

Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed adenocarcinoma of the prostate
* Report of previous surgical or medical castration
* Castration-resistant prostate cancer (CRPC) diagnosis in or before 2009
* Metastatic disease documented by positive bone scan or metastatic lesions on computed tomography or magnetic resonance imaging in or before 2009. If lymph node metastasis is the only evidence of metastasis, it must be 2 centimeters (cm) in diameter